Pudong has released a batch of innovative projects for medical industry integration to promote new drugs to meet clinical needs, guided by clinical value in biopharmaceuticals | innovation | demand
In order to strengthen the integration of the medical industry and the biopharmaceutical industry, Pudong New Area released a series of medical industry integration innovation projects on June 9th, including the "Pudong New Area Medical Industry Integration Innovation Strategy Source Platform," "Pudong New Area Clinical Research and Application Alliance," and "Eight Measures to Strengthen Medical Industry Integration Policies," further promoting wider and deeper cooperation among universities, hospitals, and enterprises in the research and development, transformation, and application fields of the biopharmaceutical industry.
It is reported that the series of medical industry integration "combination punches" launched by Pudong New Area through multi departmental cooperation aim to help Pudong New Area build a world-class biopharmaceutical industry cluster, and create a main battlefield to lead and drive China's biopharmaceutical innovation and development, a source of participation in global life technology competition, and a source of continuous emergence of "global new" products. The Municipal Health Commission, Municipal Economic and Information Commission, Municipal Science and Technology Commission, Municipal Drug Administration, Municipal Medical Insurance Bureau, Shanghai Shenkang Hospital Development Center and other departments have all provided support.
Among them, the "Pudong New Area Medical Industry Integration Innovation Strategy Source Platform" has both demand docking and service functions, which will help medical institutions, research institutions, and biopharmaceutical enterprises achieve precise and efficient docking in resources, information, projects, etc., accelerate clinical research and transformation, and promote the priority and rapid admission of innovative pharmaceutical products for use. Zhang Zhuobing, Executive Director of Junshi Biotechnology, the representative of the company, told reporters that clinical research is the foundation of innovative drugs. Through such an integrated and integrated electronic platform, it will effectively strengthen the transformation of innovative enterprises and accelerate the practical application of new drugs.
At the same time, the Pudong New Area Clinical Research and Application Alliance, composed of various committees, research institutions, medical institutions, and enterprises, will also be established. The alliance will play a bridging role, promote communication and exchange between medical and industry, establish a collaborative mechanism for medical industry integration, study and explore key and hot issues of medical industry integration, provide professional suggestions for improving medical industry integration related policies, and assist member units of the alliance in business docking such as clinical research, achievement transformation, and product promotion. The eight policies to strengthen the integration of medical and industry will provide comprehensive policy support from enhancing the level of basic research, promoting joint research between industry and medicine, accelerating the transformation of innovative achievements, and sharing clinical application risks.
On that day, Dongfang Hospital signed cooperation agreements with Junshi Biotechnology, Seventh People's Hospital with Shanghai Innovation Traditional Chinese Medicine Transformation Alliance, Pudong Hospital with Utijisheng, Gongli Hospital with Shanghai Institute of Technology with Minimally Invasive Medicine, Renji Hospital with Fosun Pharmaceuticals, and Shanghai Children's Medical Center with Tianze Yuntai in the fields of research and transformation. Seven district affiliated comprehensive hospitals, including Dongfang Hospital, Seventh People's Hospital, Pudong Hospital, Gongli Hospital, New Area People's Hospital, Zhoupu Hospital, and Punan Hospital, have signed cooperation agreements with Fosun Kate, Yaoming Jinnuo, Reckon Laser, and Bollinger Ingelheim in the field of product clinical applications.
Li Ming, Secretary of the Party Committee of Dongfang Hospital, stated that the hospital is currently simultaneously conducting clinical research funding initiated by researchers for three consecutive years. Some clinical studies, including refractory asthma, esophageal stenosis, and other diseases, have benefited many patients. Through the signing on the same day, the hospital will strengthen cooperation with biopharmaceutical enterprises, which can help more clinical projects shorten the research cycle and achieve practical application as soon as possible.
The launch of the two directories was the highlight of the day's release and an important step towards accelerating the "clinical application one kilometer" in Pudong New Area. It is reported that 45 products from 29 companies, including Sofantinib from Hutchison Whampoa, have been shortlisted for the first batch of innovative pharmaceutical product recommendation catalogs. Products included in the catalog will be admitted to hospitals within a limited time and given priority use by district medical institutions. 18 products from 12 companies, including Roche Pharmaceuticals' Mabalozavir tablets, have been shortlisted for the first batch of recommended products for key industrial enterprises. Products included in the catalog will be given priority use by regional medical institutions under equal conditions. In the future, Pudong will also establish a clinical value oriented mechanism for prioritizing the rapid application of innovative pharmaceutical products, support the development of the biopharmaceutical industry, and enable more new and good drugs to meet clinical needs, benefiting patients.
Zhu Zhisong, member of the Standing Committee of the Municipal Party Committee and Secretary of the Pudong New Area Committee, attended the event.